Comparable stake leader
TCG Crossover GP II, LLC
SEC ownership of Aura Biosciences, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001501796.
Disclosed value leader
TCG Crossover Management, LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- AURA on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
TCG Crossover GP II, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
TCG Crossover GP II, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001501796
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Aura Biosciences, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TCG Crossover GP II, LLC
Disclosed value leader
TCG Crossover Management,...
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 9.9%
13D/G row: TCG Crossover GP II, LLC
Showing 1-8 of 50 holder rows.
Quick read
TCG Crossover GP II, LLC leads the comparable SEC ownership view at 9.9%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TCG Crossover GP II, LLC's linked filing trail.
Comparable ownership
Top 5
TCG Crossover GP II, LLC
9.9%
Adage Capital Management, L.P.
8.4%
MONTANOVA CAPITAL, LLC
7.6%
Frazier Life Sciences Public Fund...
5.6%
Long Focus Capital Management, LLC
4.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TCG Crossover GP II, LLC |
13D/G
Chen Yu
|
9.9%
|
$64,540,664
9,533,333 shares
|
$0 | 05 May 2026 |
| Adage Capital Management, L.P. |
13D/G
|
8.4%
|
$64,640,487
9,104,294 shares
|
$0 | 30 Jun 2026 |
| MONTANOVA CAPITAL, LLC |
13F
13D/G
Company · Suvretta Capital Management, LLC
|
7.6%
from 13D/G
|
$51,164,141
7,206,217 shares
|
— | 30 Jun 2026 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
5.6%
|
$41,231,546
5,807,260 shares
|
+$12,603,920 | 30 Jun 2026 |
| Long Focus Capital Management, LLC |
13D/G
13F
Company
|
4.9%
|
$36,349,032
5,119,582 shares
|
+$12,780,000 | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
4.4%
from 13D/G
|
$33,424,486
4,707,674 shares
|
— | 30 Jun 2026 |
| Advent Life Sciences LLP |
13D/G
Rajesh Parekh, Ph.D.
|
3.3%
|
$11,768,148
2,071,857 shares
|
$0 | 13 Feb 2026 |
| TCG Crossover Management, LLC |
13F
Company
|
9.1%
|
$67,686,664
9,533,333 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$79,106,642.
Buys
$0
Insiders: 0
Sells
$79,106,642
Insiders: 8
Net
-$79,106,642
Shares: -14,032,601
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 14,032,601
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 12,824 | $0 | $82,330 | -$82,330 |
| 3-6 | 0 | 13,857,478 | $0 | $78,172,374 | -$78,172,374 |
| 6-9 | 0 | 123,076 | $0 | $618,783 | -$618,783 |
| 9-12 | 0 | 39,223 | $0 | $233,155 | -$233,155 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 25 reporting-owner rows connected to Aura Biosciences, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
25
Largest Forms 3/4/5 holder
Matrix Capital Management Company, LP
Net 12M change
-$79,106,643
Latest report
01 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Matrix Capital Management Company, LP | 10%+ Owner | $62,305,830 | -$39,044,987 | -39% | Filing P/S | 07 May 2026 |
| Natalie C. Holles | Chief Executive Officer and President, Director | $7,720,005 | Mixed | 19 May 2026 | ||
| Elisabet de Los Pinos | President and Chief Executive Officer, Director | $3,876,714 | -$380,830 | -8.9% | Mixed | 02 Mar 2026 |
| David M. Johnson | Director | $3,236,882 | Mixed | 11 Jun 2026 | ||
| Janet Jill Hopkins | Chief Medical Officer | $2,699,349 | -$195,960 | -6.8% | Median | 01 Sep 2026 |
| Anthony S. Gibney | Chief Financial and Business Officer. | $1,703,572 | -$82,330 | -4.6% | Filing P/S | 16 Jun 2026 |
| Julie B. Feder | Chief Financial Officer | $1,615,528 | Filing P/S | 18 Oct 2024 | ||
| Conor Kilroy | Chief Legal Officer and Secretary | $1,556,716 | -$143,400 | -8.4% | Mixed | 01 Jul 2026 |
| Mark Plavsic | Chief Technology Officer | $1,342,985 | -$157,518 | -10% | Mixed | 02 Mar 2026 |
| Amy Elazzouzi | SVP, Finance & PAO | $1,019,560 | -$56,631 | -5.3% | Median | 01 Sep 2026 |
| Susan Abu-Absi | Chief Operating Officer | $955,042 | Median | 01 Sep 2026 | ||
| Julie Person | Chief People Officer | $764,038 | Median | 01 Sep 2026 | ||
| Erica Kratz | Chief Reg. & Quality Officer | $716,283 | Median | 01 Sep 2026 | ||
| Medicxi Ventures Management (Jersey) Ltd | 10%+ Owner | $539,031 | Mixed | 02 Nov 2021 | ||
| Cadmus Rich | Chief Medical Officer, Head of R&D | $448,579 | Mixed | 19 Jan 2023 | ||
| Mark de Rosch | Chief Operating Officer | $448,059 | Mixed | 19 Jan 2023 | ||
| Antony C. Mattessich | Director | $257,565 | Mixed | 11 Jun 2026 | ||
| Sapna Srivastava | Director | $257,565 | Mixed | 11 Jun 2026 | ||
| Teresa Marie Bitetti | Director | $240,840 | Mixed | 11 Jun 2026 | ||
| Jeremy Bender | Director | $213,009 | Median | 07 Jul 2026 |
Recent insider transactions for Aura Biosciences, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Julie Person | AURA | Common Stock | Award | 107,611 | 107,611 | 01 Sep 2026 | Direct | |||
| Julie Person | AURA | Stock Option (Right to Buy) | Award | 212,389 | 212,389 | 01 Sep 2026 | Direct | |||
| Erica Kratz | AURA | Common Stock | Award | 100,885 | 100,885 | 01 Sep 2026 | Direct | |||
| Erica Kratz | AURA | Stock Option (Right to Buy) | Award | 199,115 | 199,115 | 01 Sep 2026 | Direct | |||
| Janet Jill Hopkins | AURA | Common Stock | Award | 18.3% | 58,850 | 380,190 | 01 Sep 2026 | Direct | ||
| Janet Jill Hopkins | AURA | Stock Option (Right to Buy) | Award | 116,150 | 116,150 | 01 Sep 2026 | Direct | |||
| Amy Elazzouzi | AURA | Common Stock | Award | 19.6% | 23,540 | 143,600 | 01 Sep 2026 | Direct | ||
| Amy Elazzouzi | AURA | Stock Option (Right to Buy) | Award | 46,460 | 46,460 | 01 Sep 2026 | Direct | |||
| Susan Abu-Absi | AURA | Common Stock | Award | 134,513 | 134,513 | 01 Sep 2026 | Direct | |||
| Susan Abu-Absi | AURA | Stock Option (Right to Buy) | Award | 265,487 | 265,487 | 01 Sep 2026 | Direct | |||
| Jeremy Bender | AURA | Common Stock | Award | 30,000 | 30,000 | 07 Jul 2026 | Direct | |||
| Jeremy Bender | AURA | Stock Option (Right to Buy) | Award | 60,000 | 60,000 | 07 Jul 2026 | Direct | |||
| Conor Kilroy | AURA | Common Stock | Award | 6.82% | 14,858 | 232,693 | 01 Jul 2026 | Direct | ||
| Anthony S. Gibney | AURA | Common Stock | Sale | -4.61% | $82,330 | $6.42 | -12,824 | 265,354 | 16 Jun 2026 | Direct |
| Teresa Marie Bitetti | AURA | Common Stock | Award | 71.4% | 15,000 | 36,000 | 11 Jun 2026 | Direct | ||
| Teresa Marie Bitetti | AURA | Stock Option (Right to Buy) | Award | 30,000 | 30,000 | 11 Jun 2026 | Direct | |||
| Sapna Srivastava | AURA | Common Stock | Award | 63.8% | 15,000 | 38,500 | 11 Jun 2026 | Direct | ||
| Sapna Srivastava | AURA | Stock Option (Right to Buy) | Award | 30,000 | 30,000 | 11 Jun 2026 | Direct | |||
| David Michael Johnson | AURA | Common Stock | Award | 8.37% | 15,000 | 194,167 | 11 Jun 2026 | Direct | ||
| David Michael Johnson | AURA | Stock Option (Right to Buy) | Award | 30,000 | 30,000 | 11 Jun 2026 | Direct | |||
| Antony C. Mattessich | AURA | Common Stock | Award | 63.8% | 15,000 | 38,500 | 11 Jun 2026 | Direct | ||
| Antony C. Mattessich | AURA | Stock Option (Right to Buy) | Award | 30,000 | 30,000 | 11 Jun 2026 | Direct | |||
| Natalie C. Holles | AURA | Common Stock | Award | 1,153,962 | 1,153,962 | 19 May 2026 | Direct | |||
| Natalie C. Holles | AURA | Stock Option (Right to Buy) | Award | 2,169,103 | 2,169,103 | 19 May 2026 | Direct | |||
| Matrix Capital Management Company, LP | AURA | Common Stock, par value $0.00001 per share (Common Stock) | Sale | -100% | $39,044,987 | $5.64 | -6,922,870 | 0 | 07 May 2026 | See footnotes |
| Matrix Capital Management Company, LP | AURA | Common Stock, par value $0.00001 per share (Common Stock) | Sale | -100% | $39,044,987 | $5.64 | -6,922,870 | 0 | 07 May 2026 | See footnotes |
| Conor Kilroy | AURA | Common Stock | Sale | -5.11% | $82,401 | $7.02 | -11,738 | 217,835 | 16 Apr 2026 | Direct |
| Conor Kilroy | AURA | Common Stock | Award | 37.3% | 62,339 | 229,573 | 02 Mar 2026 | Direct | ||
| Conor Kilroy | AURA | Stock Option (Right to Buy) | Award | 112,661 | 112,661 | 02 Mar 2026 | Direct | |||
| Anthony S. Gibney | AURA | Common Stock | Award | 34.4% | 71,245 | 278,178 | 02 Mar 2026 | Direct | ||
| Anthony S. Gibney | AURA | Stock Option (Right to Buy) | Award | 128,755 | 128,755 | 02 Mar 2026 | Direct | |||
| Elisabet de Los Pinos | AURA | Common Stock | Award | 40.5% | 166,000 | 575,815 | 02 Mar 2026 | Direct | ||
| Elisabet de Los Pinos | AURA | Stock Option (Right to Buy) | Award | 249,000 | 249,000 | 02 Mar 2026 | Direct | |||
| Mark Plavsic | AURA | Common Stock | Award | 34.4% | 62,339 | 243,736 | 02 Mar 2026 | Direct | ||
| Mark Plavsic | AURA | Stock Option (Right to Buy) | Award | 112,661 | 112,661 | 02 Mar 2026 | Direct | |||
| Janet Jill Hopkins | AURA | Common Stock | Award | 38.3% | 89,056 | 321,340 | 02 Mar 2026 | Direct | ||
| Janet Jill Hopkins | AURA | Stock Option (Right to Buy) | Award | 160,944 | 160,944 | 02 Mar 2026 | Direct | |||
| Amy Elazzouzi | AURA | Common Stock | Award | 59% | 44,528 | 120,060 | 02 Mar 2026 | Direct | ||
| Amy Elazzouzi | AURA | Stock Option (Right to Buy) | Award | 80,472 | 80,472 | 02 Mar 2026 | Direct | |||
| Conor Kilroy | AURA | Common Stock | Sale | -6.74% | $60,999 | $5.05 | -12,079 | 167,234 | 17 Feb 2026 | Direct |
| Mark Plavsic | AURA | Common Stock | Sale | -8.05% | $80,244 | $5.05 | -15,890 | 181,397 | 17 Feb 2026 | Direct |
| Janet Jill Hopkins | AURA | Common Stock | Sale | -8.07% | $103,229 | $5.06 | -20,401 | 232,284 | 17 Feb 2026 | Direct |
| Amy Elazzouzi | AURA | Common Stock | Sale | -10.2% | $43,258 | $5.06 | -8,549 | 75,532 | 17 Feb 2026 | Direct |
| Elisabet de Los Pinos | AURA | Common Stock | Sale | -10.4% | $241,099 | $5.06 | -47,648 | 409,815 | 17 Feb 2026 | Direct |
| Amy Elazzouzi | AURA | Common Stock | Sale | -1.85% | $7,684 | $4.86 | -1,581 | 84,081 | 20 Jan 2026 | Direct |
| Elisabet de Los Pinos | AURA | Common Stock | Sale | -3.57% | $82,270 | $4.86 | -16,928 | 457,463 | 20 Jan 2026 | Direct |
| Janet Jill Hopkins | AURA | Common Stock | Sale | -6.34% | $92,731 | $5.42 | -17,109 | 252,685 | 17 Nov 2025 | Direct |
| Amy Elazzouzi | AURA | Common Stock | Sale | -1.04% | $5,690 | $6.35 | -896 | 85,662 | 29 Oct 2025 | Direct |
| Elisabet de Los Pinos | AURA | Common Stock | Sale | -1.87% | $57,461 | $6.35 | -9,049 | 474,391 | 29 Oct 2025 | Direct |
| Mark Plavsic | AURA | Common Stock | Sale | -5.81% | $77,273 | $6.35 | -12,169 | 197,287 | 16 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.